Brokerages predict that Nu Skin Enterprises, Inc. (NYSE:NUS) will announce sales of $642.84 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Nu Skin Enterprises’ earnings, with the lowest sales estimate coming in at $640.50 million and the highest estimate coming in at $644.27 million. Nu Skin Enterprises reported sales of $550.10 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16.9%. The company is expected to announce its next quarterly earnings report after the market closes on Thursday, August 2nd.
On average, analysts expect that Nu Skin Enterprises will report full-year sales of $2.54 billion for the current fiscal year, with estimates ranging from $2.53 billion to $2.55 billion. For the next fiscal year, analysts anticipate that the business will report sales of $2.63 billion per share, with estimates ranging from $2.59 billion to $2.68 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Nu Skin Enterprises.
Get Nu Skin Enterprises alerts:
Nu Skin Enterprises (NYSE:NUS) last posted its earnings results on Thursday, April 26th. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.70 by $0.09. The company had revenue of $616.00 million during the quarter, compared to analyst estimates of $564.46 million. Nu Skin Enterprises had a return on equity of 25.36% and a net margin of 5.74%. The business’s revenue was up 23.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.51 earnings per share.
A number of equities analysts recently issued reports on the company. ValuEngine raised Nu Skin Enterprises from a “buy” rating to a “strong-buy” rating in a report on Monday, April 2nd. Zacks Investment Research lowered Nu Skin Enterprises from a “hold” rating to a “sell” rating in a report on Monday. Jefferies Financial Group assumed coverage on Nu Skin Enterprises in a report on Thursday, June 14th. They issued a “buy” rating and a $98.00 price objective for the company. Citigroup increased their price objective on Nu Skin Enterprises from $81.00 to $82.00 and gave the stock a “buy” rating in a report on Monday, April 30th. Finally, Deutsche Bank lowered Nu Skin Enterprises from a “buy” rating to a “hold” rating and set a $77.00 price objective for the company. in a report on Friday, April 13th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Nu Skin Enterprises currently has a consensus rating of “Hold” and a consensus target price of $77.00.
In other Nu Skin Enterprises news, General Counsel D Matthew Dorny sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $77.65, for a total value of $271,775.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Neil H. Offen sold 7,000 shares of the company’s stock in a transaction that occurred on Thursday, June 7th. The stock was sold at an average price of $81.66, for a total value of $571,620.00. Following the completion of the sale, the director now owns 11,267 shares of the company’s stock, valued at $920,063.22. The disclosure for this sale can be found here. Insiders sold a total of 27,000 shares of company stock valued at $2,071,970 over the last three months. Corporate insiders own 5.20% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NUS. Millennium Management LLC lifted its position in Nu Skin Enterprises by 937.5% in the first quarter. Millennium Management LLC now owns 422,098 shares of the company’s stock worth $31,113,000 after purchasing an additional 381,414 shares during the period. Mackay Shields LLC acquired a new stake in shares of Nu Skin Enterprises during the 1st quarter valued at $23,903,000. Renaissance Technologies LLC acquired a new stake in shares of Nu Skin Enterprises during the 4th quarter valued at $13,373,000. UBS Asset Management Americas Inc. lifted its position in shares of Nu Skin Enterprises by 381.4% during the 4th quarter. UBS Asset Management Americas Inc. now owns 224,985 shares of the company’s stock valued at $15,351,000 after acquiring an additional 178,250 shares during the last quarter. Finally, OppenheimerFunds Inc. lifted its position in shares of Nu Skin Enterprises by 1,497.3% during the 1st quarter. OppenheimerFunds Inc. now owns 148,041 shares of the company’s stock valued at $10,912,000 after acquiring an additional 138,773 shares during the last quarter. Hedge funds and other institutional investors own 76.20% of the company’s stock.
Shares of Nu Skin Enterprises traded up $0.73, hitting $78.75, during trading on Thursday, Marketbeat Ratings reports. 374,500 shares of the company traded hands, compared to its average volume of 503,199. The firm has a market capitalization of $4.34 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 2.39 and a beta of 1.38. Nu Skin Enterprises has a one year low of $53.50 and a one year high of $84.00. The company has a current ratio of 1.14, a quick ratio of 0.75 and a debt-to-equity ratio of 0.13.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 13th. Investors of record on Friday, May 25th were issued a $0.365 dividend. This represents a $1.46 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date of this dividend was Thursday, May 24th. Nu Skin Enterprises’s dividend payout ratio (DPR) is 45.20%.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
